Denali Therapeutics Inc. DNLI
Super Investor & Insider
1
Fondi che lo detengono
#1317
Rank consenso
1.4%
% dei portafogli
$1.3M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Polen Capital Management · Polen Capital Management | 0.01% | Add 142.75% | 65,301 | $1.3M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing therapeutics to address neurodegenerative and lysosomal storage diseases. The company engineers product candidates using proprietary technologies such as Antibody Transport Vehicle (ATV) and Enzyme Transport Vehicle (ETV) to e…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees507
TickerDNLI
Statistics
Market Cap$3.73B
Revenue (TTM)$0
Net Income-$512.5M
Net Margin—
EPS$-2.97
P/E-7.07
P/S—
P/B3.60
EV/EBITDA-4.37
ROE-49.6%
Dividend Yield—
Price$23.48
Data: Twelve Data · Revenue = mcap / P/S